+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel



Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel



Alimentary Pharmacology and Therapeutics 48(8): 780-796



Clopidogrel's anti-platelet effects may be attenuated by a pharmacokinetic interaction with co-prescribed proton pump inhibitors, which inhibit oxidative pathways that convert clopidogrel into its active metabolites. Despite this, the impact of PPIs on cardiovascular risk in the absence of clopidogrel is not well defined. To report on a systematic review and meta-analysis of the association between PPIs and cardiovascular risk, independent of clopidogrel. The databases of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, Web of Science, and ClinicalTrials.gov were systematically searched in October 2017. The primary outcome was association between PPI monotherapy and any adverse cardiovascular event. The secondary outcome was association between proton pump inhibitor monotherapy and acute myocardial infarction. Studies were excluded if they reported or did not adjust for concomitant anti-platelet therapy or involved participants aged less than 18 years. A total of 22 studies were included in the systematic review. Data from 16 studies were included in the meta-analysis (involving 447 408 participants). Of these, eight were randomised controlled trials, seven were observational studies and one was a retrospective analysis of a randomised controlled trial. An increased risk of any adverse cardiovascular event with PPI monotherapy was observed using pooled data from observational studies (risk ratio 1.25, 95% CI 1.11-1.42, I2 81%, P < 0.001), but not from randomised controlled trials (risk ratio 0.89, 95% CI 0.34-2.33, I2 0%, P = 0.85). There is no clear evidence of an association between PPI monotherapy and increased cardiovascular risk.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065932001

Download citation: RISBibTeXText

PMID: 30178881

DOI: 10.1111/apt.14955


Related references

T1078 Risk of Adverse Cardiovascular Events With Concomitant use of Clopidogrel and Proton Pump Inhibitors(Ppi): Systematic Review and Meta-Analysis of Observational Studies. Gastroenterology 138(5): S-483, 2010

Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Safety 34(1): 47-57, 2011

Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Archives of Medical Research 43(3): 212-224, 2012

Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016). Bmc Cardiovascular Disorders 17(1): 3, 2017

Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. Journal of Cardiovascular Pharmacology and Therapeutics 22(2): 142-152, 2017

460 Effects of Proton-Pump Inhibitors in Patients Receiving Clopidogrel-Based Antithrombotic Therapy for Cardiovascular Prevention: A Systematic Review and Meta-Analysis of Randomized Trials. Gastroenterology 156(6): S-97, 2019

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Alimentary Pharmacology and Therapeutics 31(8): 810-823, 2010

Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart 2(1): E000248, 2015

Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?. Gastroenterology 137(3): 1168-1171, 2009

No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. International Journal of Cardiology 167(3): 965-974, 2013

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis 8(12): 2624-2641, 2010

Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Alimentary Pharmacology and Therapeutics 35(1): 165-174, 2012

Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. Journal of Gastroenterology 46(1): 39-45, 2011

Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology 30(12): 1395-1405, 2018

Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. Journal of Gastroenterology 48(7): 830-838, 2013